TITLE

Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing project

AUTHOR(S)
Hadfield, S G; Horara, S; Starr, B J; Yazdgerdi, S; Bhatnagar, D; Cramb, R; Egan, S; Everdell, R; Ferns, G; Jones, A; Marenah, C B; Marples, J; Prinsloo, P; Sneyd, A; Stewart, M F; Sandle, L; Wang, T; Watson, M S; Humphries, S E
PUB. DATE
March 2008
SOURCE
Annals of Clinical Biochemistry;Mar2008, Vol. 45 Issue 2, p199
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Familial hypercholesterolaemia (FH) is an autosomal co-dominant disorder which is relatively common, leads to high levels of LDL-cholesterol and if untreated to early coronary heart disease. An audit of current practice at National Health Service Trusts in England was undertaken to determine whether FH patients meet the diagnostic criteria for FH; are being offered appropriate advice and treatment; and to what extent their families are contacted and offered testing for the disorder. Methods: Medical records of known FH patients (over 18 years of age and diagnosed before 31 December 2003) were accessed to obtain information on diagnosis, treatment and family tracing. Results: The records of 733 FH patients were examined, 79% met the UK 'Simon Broome' register criteria for the diagnosis of definite or possible FH. Analyses showed that patients were usually offered appropriate advice and treatment, with 89% being on a statin. However, the audit indicated a high variability in family tracing between the sites, with significant differences in the frequency of inclusion of a family pedigree in the notes (range 1–71%, mean 35%); the general practitioner (GP) being advised that first-degree relatives should be tested (range 4–52%, mean 27%); and the proportion of relatives contacted and tested (range 6–50%, mean 32%). Conclusion: FH patients are well cared for in lipid clinics in England, are being given appropriate lifestyle advice and medication, but an increase in recording of LDL-cholesterol levels may lead to improvements in their management. Practice in family tracing appears to vary widely between clinics.
ACCESSION #
31139837

 

Related Articles

  • Management of hyperlipidaemia after coronary revascularisation: Follow up study. Delacretaz, Etienne; Michalopoulos, Petros G.; Ruiz, Juan; Saner, Hugo; Meier, Bernhard // BMJ: British Medical Journal (International Edition);05/16/98, Vol. 316 Issue 7143, p1499 

    Presents a follow-up study of the management of hyperlipidaemia after coronary revascularisation in 245 patients. How much of these patients had angioplasty and bypass grafting; Details on baseline concentrations; Indication that only a few patients with hypercholesterolaemia received adequate...

  • Hyperlipidemia advances and retreats.  // British Medical Journal;8/2/1980, Vol. 281 Issue 6236, p340 

    Examines the correlation between hyperlipidemia and ischemic heart failure. Attempts in lowering serum lipid concentrations; Feasibility of primary drugs in preventing ischemic heart disease; Effects of diet, control of hypertension and advice against smoking in selected population at high risk...

  • Hyperlipidemia and coronary heart disease in women.  // American Family Physician;3/1/1996, Vol. 53 Issue 4, p1411 

    Reports on a study published in the 1995 issue of the `Journal of the American Medical Association' periodical by Walsh and Grady who assessed the effects of dietary or drug management of hyperlipidemia or the elevated levels of total cholesterol and low-density lipoprotein (LDL) cholesterol on...

  • What should be done about asymptomatic hypercholesterolaemia? Thompson, Gilbert R. // BMJ: British Medical Journal (International Edition);2/16/91, Vol. 302 Issue 6773, p605 

    Focuses on the clinical management of patients with asymptomatic hypercholesterolemia in Canada. Decrease in mortality from coronary heart disease; Influence of hypercholesterolemia on the relative increase of the risk for coronary heart disease; Measurement of serum total cholesterol...

  • New Solutions in the Management of Hypercholesterolemia. Lipsy, Robert J. // Formulary;Feb2004 Supplement 2, Vol. 39, p8 

    Reports that the U.S. National Cholesterol Education Program (NCEP) has released the updated Adult Treatment Panel III (ATP III) guidelines in May 2001. Provision of healthcare professionals with an up-to-date approach for the detection, evaluation and management of dyslipidemia; Focus of ATP...

  • Revised NCEP Guidelines for the Management of Hypercholesterolemia: An Overview. Straka, Robert J. // Formulary;Feb2004 Supplement 2, Vol. 39, p16 

    Points out that a major focus of the revised guidelines of the U.S. National Cholesterol Education Program Adult Treatment Panel III for cholesterol testing and management is on primary prevention in persons with multiple risk factors. Expansion of the clinical indications for intensive...

  • Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed? Wierzbicki, Anthony S.; Graham, Colin A.; Young, Ian S.; Nicholls, D. Paul // Current Vascular Pharmacology;Jan2008, Vol. 6 Issue 1, p13 

    Familial combined hyperlipidaemia (FCH) was identified in early genetic studies of populations as a dominant condition associated with mixed hyperlipidaemia and early onset coronary heart disease. Later studies extended the phenotype and noted that this genetic hyperlipidaemia was sensitive to...

  • Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. Yuan, George; Jian Wang; Hegele, Robert A. // CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1124 

    Heterozygous familial hypercholesterolemia (HeFH) is a monogenic disorder that affects about 1 in 500 people, with a higher prevalence in certain subpopulations such as people of Quebecois, Christian Lebanese and Dutch South Afrikaner extraction. HeFH is characterized by cholesterol deposits...

  • Cardiovascular events costly in high-risk patients.  // PharmacoEconomics & Outcomes News;Jun2015, Vol. 730 Issue 1, p9 

    The article discusses research being done on the costs associated with cardiovascular events among patients with hyperlipidemia, which references a study by M. M. Bonafede et al. published in the June 9, 2015 issue of the journal "ClinicoEconomics and Outcomes Research."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics